|
KMID : 0371420190960040185
|
|
Annals of Surgical Treatment and Research
2019 Volume.96 No. 4 p.185 ~ p.190
|
|
|
Actual compliance to adjuvant chemotherapy in gastric cancer
|
|
Kim Dong-Wook
Kwon Oh-Kyoung
Yoo Moon-Won
Ryu Seung-Wan
Oh Sung-Jin
Hur Hoon
Hwang Sun-Hwi
Lee Jun-Hyun
Jin Sung-Ho
Lee Sang-Eok
Kim Jong-Han
Kim Jin-Jo
Jeong In-Ho
Jee Ye-Seob
|
|
|
Abstract
|
|
|
Purpose: This study aims to investigate the actual compliance with chemotherapy and analyze several factors affecting the compliance in patients with gastric cancer.
Methods: From February 2012 to December 2014, we collected data of patients with gastric cancer who received adjuvant chemotherapy (TS-1 monotherapy or XELOX: capecitabine/oxaliplatin) in Korea.
Results: We collected data of 1,089 patients from 31 institutions. The completion rate and dose reduction rate by age (≥60 years vs. <60 years) were 57.5% vs. 76.8% (P < 0.001) and 17.9% vs. 21.3% (P = 0.354); by body mass index (BMI) (≥23 kg/m2 vs. <23 kg/m2) were 70.2% vs. 63.2% (P = 0.019) and 19.2% vs. 19.9% (P = 0.987), respectively. The compliance by American Society of Anesthesiologists physical status (ASA PS) classification was as follows: completion rate was 74.4%, 62.8%, and 60% (P = 0.001) and the dose reduction rate was 18.4%, 20.7%, and 17.8% (P = 0.946) in ASA PS classification I, II, and III, respectively. The completion rate of TS-1 and XELOX was 65.9% vs. 70.3% (P = 0.206) and the dose reduction rate was 15.7% vs. 33.6% (P < 0.001). Furthermore, the completion rate of chemotherapy by surgical oncologists and medical oncologists was 69.5% vs. 63.2% (P = 0.028) and the dose reduction rate was 17.4% vs. 22.3% (P = 0.035), respectively.
Conclusion: The compliance was lower in patients who were older than 60 years, had BMI <23 kg/m2, and had higher ASA PS classification. Furthermore, the patients showed higher compliance when they received chemotherapy from surgical oncologists rather than from medical oncologists.
|
|
|
KEYWORD
|
|
|
Compliance, Adjuvant chemotherapy, Advanced gastric cancer
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
   
|
|